127 related articles for article (PubMed ID: 2481193)
1. Profile of cardiac and coronary vasodilator effects of MS-857, a novel cardiotonic agent, assessed in isolated, blood-perfused heart preparations of the dog.
Maruyama M; Kamiya J; Kobari T
J Cardiovasc Pharmacol; 1989 Nov; 14(5):777-82. PubMed ID: 2481193
[TBL] [Abstract][Full Text] [Related]
2. Cardiac and coronary vasodilator effects of the novel cardiotonic agent, MCI-154, assessed in isolated, blood-perfused dog heart preparations.
Hosono M; Taira N
J Cardiovasc Pharmacol; 1987 Dec; 10(6):692-8. PubMed ID: 2450240
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of MDL 17043 and MDL 19205, new positive inotropic agents, by use of isolated, blood-perfused dog-heart preparations.
Wada Y; Taira N
Heart Vessels; 1986; 2(1):29-35. PubMed ID: 2941407
[TBL] [Abstract][Full Text] [Related]
4. Coronary vasodilator and cardiac effects of NKY-722, a novel hydrophilic 1,4-dihydropyridine derivative, in the blood-perfused dog heart.
Imagawa J; Satoh K; Taira N
Cardiovasc Drugs Ther; 1989 Mar; 3(1):81-90. PubMed ID: 2487526
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and coronary vasodilator profile of pimobendan, a new cardiotonic drug, revealed by use of isolated, blood-perfused dog heart preparations.
Imagawa J; Satoh K; Taira N
Heart Vessels; 1987; 3(4):182-9. PubMed ID: 3453824
[TBL] [Abstract][Full Text] [Related]
6. Inotropic versus chronotropic, dromotropic, and coronary vasodilator actions of DPI 201-106, a novel positive inotropic agent, in the dog heart.
Takahashi K; Endoh M; Taira N
J Cardiovasc Pharmacol; 1987 Apr; 9(4):451-60. PubMed ID: 2438508
[TBL] [Abstract][Full Text] [Related]
7. Selectivity of alinidine, a bradycardic agent, for SA nodal automaticity versus other cardiac activities in isolated, blood-perfused dog-heart preparations.
Kawada M; Satoh K; Taira N
Arch Int Pharmacodyn Ther; 1984 Nov; 272(1):88-102. PubMed ID: 6517649
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of coronary vasodilator and cardiac effects of nitrendipine by use of isolated, blood-perfused dog heart preparations.
Satoh K; Wada Y; Taira N
Arzneimittelforschung; 1986; 36(1):35-9. PubMed ID: 2937413
[TBL] [Abstract][Full Text] [Related]
9. Are the cardiovascular effects of gentamicin similar to those of calcium antagonists?
Gotanda K; Yanagisawa T; Satoh K; Taira N
Jpn J Pharmacol; 1988 Jul; 47(3):217-27. PubMed ID: 3221528
[TBL] [Abstract][Full Text] [Related]
10. Profile of coronary vasodilator and cardiac actions of bepridil revealed by use of isolated, blood-perfused heart preparations of the dog.
Kawada M; Satoh K; Taira N
J Cardiovasc Pharmacol; 1983; 5(4):604-12. PubMed ID: 6193358
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of cardiovascular profiles of milrinone and amrinone by use of isolated, blood-perfused dog heart preparations.
Sato Y; Wada Y; Taira N
Heart Vessels; 1986; 2(4):213-20. PubMed ID: 3571104
[TBL] [Abstract][Full Text] [Related]
12. Separation of the coronary vasodilator from the cardiac effects of PN 200-110, a new dihydropyridine calcium antagonist, in the dog heart.
Wada Y; Satoh K; Taira N
J Cardiovasc Pharmacol; 1985; 7(1):190-6. PubMed ID: 2580142
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular profile of Ro 40-5967, a new nondihydropyridine calcium antagonist, delineated in isolated, blood-perfused dog hearts.
Orito K; Satoh K; Taira N
J Cardiovasc Pharmacol; 1993 Aug; 22(2):293-9. PubMed ID: 7692172
[TBL] [Abstract][Full Text] [Related]
14. Analyses of the cardiac action of the bradycardic agent, AQ-A 39, by use of isolated, blood-perfused dog-heart preparations.
Kawada M; Satoh K; Taira N
J Pharmacol Exp Ther; 1984 Feb; 228(2):484-90. PubMed ID: 6694121
[TBL] [Abstract][Full Text] [Related]
15. Cardioselective effects of gallopamil compared with verapamil in the dog heart.
Takahashi K; Tsuchida K; Aihara H
Arch Int Pharmacodyn Ther; 1988; 295():157-73. PubMed ID: 3245731
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular profile of Bay K 8644, a presumed calcium channel activator, in the dog.
Wada Y; Satoh K; Taira N
Naunyn Schmiedebergs Arch Pharmacol; 1985 Feb; 328(4):382-7. PubMed ID: 2581147
[TBL] [Abstract][Full Text] [Related]
17. Coronary vasodilator compared to cardiac effects of PY 108-068, a new dihydropyridine vasodilator, on isolated, blood-perfused dog-heart preparations.
Wada Y; Satoh K; Taira N
J Cardiovasc Pharmacol; 1984; 6(5):881-7. PubMed ID: 6209495
[TBL] [Abstract][Full Text] [Related]
18. Coronary vasodilator versus cardiac effects of MCI-176, a novel quinazolinone calcium antagonist, in the dog heart.
Hosono M; Taira N
J Cardiovasc Pharmacol; 1987 Jun; 9(6):633-40. PubMed ID: 2442528
[TBL] [Abstract][Full Text] [Related]
19. Mode and mechanism of action of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- quinolinone (OPC-8212), a novel positive inotropic drug, on the dog heart.
Taira N; Endoh M; Iijima T; Satoh K; Yanagisawa T; Yamashita S; Maruyama M; Kawada M; Morita T; Wada Y
Arzneimittelforschung; 1984; 34(3A):347-55. PubMed ID: 6331465
[TBL] [Abstract][Full Text] [Related]
20. Cardiac versus coronary vasodilator actions of isobutylmethylxanthine in dogs: comparison with theophylline.
Takahashi K; Wada Y; Taira N
Jpn J Pharmacol; 1986 May; 41(1):23-32. PubMed ID: 2426501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
